Research synthesis
Does leucovorin (folinic acid) help autistic children?
Small trials hint at better talking — but the evidence is thin, mostly from one research group, and the largest trial was retracted.
Spectrum Connect reviews published research on interventions parents are exploring for their autistic children — so you can see where the evidence actually stands. No agenda, no selling, no cherry-picking. Just the studies, our method, and what it means for you.
Important — please read this first. Leucovorin is a prescription medicine. In March 2026 the US FDA approved it for one rare, genetic form of cerebral folate deficiency — not for autism. Please talk with your child’s doctor before starting or stopping it. High doses can hide the blood signs of low vitamin B12 while nerve damage continues, and it must not be used in a rare condition called MTHFS deficiency.
Key Takeaways
Small trials found some improvement in talking — three small placebo-controlled trials (48, 19 and 55 children) reported gains. In the trial of 48 children, talking improved more on leucovorin than on the dummy pill. How sure we are: low.
A fourth trial was retracted — a 2024 trial was retracted in January 2026, and we did not count it. It appears to be the trial that reported the largest effect. Without it, only one trial of 19 children speaks to overall autism signs.
Most of the evidence comes from one research group — including the main 2021 review, whose authors include that group’s lead trialist. Experts writing in 2026 said some results would not hold up once you account for how many things were measured, and that blinding was not always good enough.
The antibody question can’t be acted on yet — children with folate-blocking antibodies seemed to improve more in one trial, but there is no FDA-cleared or approved test for those antibodies.
Talk it through with your child’s doctor — if you are considering leucovorin, it is reasonable to ask whether your child has signs of cerebral folate deficiency, how progress would be checked, what dose is planned, and whether vitamin B12 should be checked first.
What this means for you
Leucovorin, also called folinic acid, is a form of the B vitamin folate. It is used in cancer care and for cerebral folate deficiency, a rare condition where folate cannot get into the brain. Some researchers think a group of autistic children have low folate in the brain, often linked to antibodies that block folate from getting in — and that leucovorin may get around that block. In a few small, fair tests (randomized, with a dummy pill), children’s talking improved on leucovorin.
Those tests are small, and most come from one research group — including the 2021 review that pooled them, which mostly drew on studies without a comparison group. A fourth trial, published in 2024, was retracted in January 2026, so we did not count it. We do not yet know whether leucovorin helps most autistic children, and we found no long-term results.
The news around this medicine has been loud. In September 2025 the US government announced it would move leucovorin toward approval. In March 2026 the FDA approved it only for one genetic form of cerebral folate deficiency, not for autism. The American Academy of Pediatrics says current evidence is insufficient to support prescribing leucovorin for autism in the absence of cerebral folate deficiency.
Who was studied. Autistic children, in trials comparing oral leucovorin with a dummy pill; one trial (55 children, from an independent research group in Iran) gave it alongside other treatment. Trials mostly measured talking and language, or autism rating scales filled in by parents or clinicians. We did not capture how long each trial lasted or each trial’s dose, and we found no results for older children or adults. Generalizability beyond this population is not established.
Where the studies landed
Promising but contestedTap a band to see what those studies actually said.
One trial here was retracted. A 2024 randomized trial was retracted in January 2026. A 2026 expert editorial still lists it among four trials. We excluded it from every verdict on this page (tap the red tile for details).
Points toward it helping4
Mixed or inconclusive1
Retracted — excluded1
Each tile is one source. The ringed tile is a review that pools many studies — here, mostly studies without a comparison group.
See the research behind this
Search strategy, PRISMA flow & evidence strength — 5 sources
Where we looked
This run was a scoping search, not a full database search. We ran 2 general web searches (19 results) and 13 targeted page fetches, of which 5 could be read — several PubMed and PMC pages were blocked by bot checks, and some DOI lookups were rate-limited. That means we can’t publish per-database counts or a formal PRISMA flow for this run. Below is the search a full run executes against PubMed/MEDLINE, Embase, APA PsycINFO, Cochrane CENTRAL, Epistemonikos, trial registers, and the Retraction Watch Database and Crossref update records.
("Leucovorin"[MeSH] OR leucovorin[tiab] OR "folinic acid"[tiab] OR "calcium folinate"[tiab] OR "cerebral folate"[tiab]) AND ("Autism Spectrum Disorder"[MeSH] OR autis*[tiab] OR "ASD"[tiab])
Run on PubMed →
What we did with what we found
What the strongest evidence says
Three small trials (122 children) reported gains on different speech measures. In the 48-child trial, the effect on verbal communication was Cohen’s d = 0.70. Small samples, mostly one research group, and some results may not survive correction for multiple comparisons.
After the retraction, one trial of 19 children remains: ADOS scores improved 2.78 points on leucovorin vs 0.4 on placebo. Too little research to judge. The same goes for children with folate-blocking antibodies, where no approved test exists.
Usually mild but real: agitation, aggression, trouble sleeping, headaches, irritability, stomach upset and rash have been reported. Separately, the medicine’s label-level risks apply: high doses can mask low vitamin B12, and it must not be used in MTHFS deficiency.
Reviewed by Ray Kawai, BCAT · not medical advice
We publish the whole record so it can be checked — and that only counts if we act on what you find. If a number looks wrong, a study is missing or has been retracted, or we’ve read a finding in a way the evidence doesn’t support, tell us.
You don’t need a research background to file one. “This doesn’t match what our doctor told us” is a useful report. Every one reaches a person: we reply within seven days, and within thirty we have either corrected the page or told you when we will. Substantive reports send the affected steps back through the protocol and need fresh sign-off before anything here changes.
Report a factual error